Dilon Expands Device Portfolio with the Addition of a Reposable Version of MarginProbe®

By Jul 11, 2018 July 30th, 2018 News, Provider Resources, Uncategorized

The Reposable MarginProbe, which is used to detect residual cancer during lumpectomy procedures, has received CE Mark approval.

July 11, 2018 (Alpharetta, Ga.) – Hospitals produce more than 4.67 million tons of waste each year causing more health system executives and clinicians to focus on reducing their system’s environmental footprint.1 With sustainability in mind, Dune designed a reposable version of MarginProbe. The new reposable MarginProbe has a reusable cable and handle and a single-use attachable probe. The new probe has the potential to reduce waste burden of MarginProbe up to 50%.

Built upon Dune’s proprietary RF Spectroscopy platform, the probe is identical in performance to the current MarginProbe and is compatible with all existing MarginProbe consoles.

“The reposable version of MarginProbe is the latest example of Dune’s commitment to bringing customer centric innovation to market, ensuring that we are fully in sync to the changing face of healthcare.” says Lori Chmura, CEO of Dilon.

Since receiving FDA approval, MarginProbe system has successfully demonstrated a consistent and significant reduction in re-excisions in breast cancer lumpectomy procedures. The growing body of MarginProbe published evidence supports a reduction of rates anywhere between 50-79%. The most recent published study by Kupstas, et. al.,  reported a reduction of positive margins after lumpectomy leading to a reduction in the number of re-excisions by 61%.

The reposable device will first be introduced to the Israeli market, followed closely by launch in the EU. Successful commercialization in these markets will act as a catalyst for US FDA submission.


About Dilon Devices
Imagine not having to wonder, did we get it all?
At Dilon Devices, we believe in reducing the anxiety that waiting for pathology results places on a patient and their families. Our solutions, which are developed on a first-of-its kind RF Spectroscopy platform can differentiate cancerous from healthy tissue based on electromagnetic properties, making it possible for patients and physicians to answer the question, “Did we get it all?”


Media contact
Paul Snyder
Vice President, Healthcare
Write2Market for Dilon Devices


  1. Sanbon BJ. Hospitals save millions with sustainability programs, cut back on waste. Healthcare Finance. March 14, 2017. http://www.healthcarefinancenews.com/news/hospitals-save-millions-sustainability-programs-cut-back-waste